Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions

Standard

Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. / Bernreuther, Christian; Daghigh, Ferdous; Möller, Katharina; Hube-Magg, Claudia; Lennartz, Maximilian; Lutz, Florian; Rico, Sebastian Dwertmann; Fraune, Christoph; Dum, David; Luebke, Andreas M; Eichenauer, Till; Möller-Koop, Christina; Schlomm, Thorsten; Wittmer, Corinna; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Haese, Alexander; Burandt, Eike; Tsourlakis, Maria Christina; Clauditz, Till S; Höflmayer, Doris; Izbicki, Jakob R; Simon, Ronald; Sauter, Guido; Minner, Sarah; Steurer, Stefan; Meiners, Jan.

in: PATHOL ONCOL RES, Jahrgang 26, Nr. 4, 10.2020, S. 2709-2722.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{69d72522b5c64bec9bc2be77f683603d,
title = "Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions",
abstract = "Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immunohistochemistry. SFRP4 expression was higher in cancer than in non-neoplastic acinar cells. SFRP4 staining was seen in 64.9% of tumors and classified as weak in 33.2%, moderate in 23.9% and strong in 7.8% of cancers. SFRP4 overexpression was linked to advanced tumor stage, high classical/quantitative Gleason grade (p < 0.0001 each), lymph node metastasis (p = 0.0002), and a positive surgical margin (p = 0.0017). SFRP4 positivity was markedly more frequent in ERG positive (77.4%) than in ERG negative cancers (57.4% p < 0.0001). Subset analyses in 2725 cancers with and 3592 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. In a multivariate analysis including various postoperative and prognostic clinico-pathological features, SFRP4 protein expression emerged as an independent prognostic parameter in ERG negative cancers. SFRP4 immunostaining was significantly linked with 10 of 11 previously analyzed chromosomal deletions (p < 0.05 each). In conclusion, high SFRP4 immunostaining is associated with poor prognosis and genomic instability in ERG negative prostate cancers.",
author = "Christian Bernreuther and Ferdous Daghigh and Katharina M{\"o}ller and Claudia Hube-Magg and Maximilian Lennartz and Florian Lutz and Rico, {Sebastian Dwertmann} and Christoph Fraune and David Dum and Luebke, {Andreas M} and Till Eichenauer and Christina M{\"o}ller-Koop and Thorsten Schlomm and Corinna Wittmer and Hartwig Huland and Hans Heinzer and Markus Graefen and Alexander Haese and Eike Burandt and Tsourlakis, {Maria Christina} and Clauditz, {Till S} and Doris H{\"o}flmayer and Izbicki, {Jakob R} and Ronald Simon and Guido Sauter and Sarah Minner and Stefan Steurer and Jan Meiners",
year = "2020",
month = oct,
doi = "10.1007/s12253-020-00861-9",
language = "English",
volume = "26",
pages = "2709--2722",
journal = "PATHOL ONCOL RES",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

RIS

TY - JOUR

T1 - Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions

AU - Bernreuther, Christian

AU - Daghigh, Ferdous

AU - Möller, Katharina

AU - Hube-Magg, Claudia

AU - Lennartz, Maximilian

AU - Lutz, Florian

AU - Rico, Sebastian Dwertmann

AU - Fraune, Christoph

AU - Dum, David

AU - Luebke, Andreas M

AU - Eichenauer, Till

AU - Möller-Koop, Christina

AU - Schlomm, Thorsten

AU - Wittmer, Corinna

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Haese, Alexander

AU - Burandt, Eike

AU - Tsourlakis, Maria Christina

AU - Clauditz, Till S

AU - Höflmayer, Doris

AU - Izbicki, Jakob R

AU - Simon, Ronald

AU - Sauter, Guido

AU - Minner, Sarah

AU - Steurer, Stefan

AU - Meiners, Jan

PY - 2020/10

Y1 - 2020/10

N2 - Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immunohistochemistry. SFRP4 expression was higher in cancer than in non-neoplastic acinar cells. SFRP4 staining was seen in 64.9% of tumors and classified as weak in 33.2%, moderate in 23.9% and strong in 7.8% of cancers. SFRP4 overexpression was linked to advanced tumor stage, high classical/quantitative Gleason grade (p < 0.0001 each), lymph node metastasis (p = 0.0002), and a positive surgical margin (p = 0.0017). SFRP4 positivity was markedly more frequent in ERG positive (77.4%) than in ERG negative cancers (57.4% p < 0.0001). Subset analyses in 2725 cancers with and 3592 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. In a multivariate analysis including various postoperative and prognostic clinico-pathological features, SFRP4 protein expression emerged as an independent prognostic parameter in ERG negative cancers. SFRP4 immunostaining was significantly linked with 10 of 11 previously analyzed chromosomal deletions (p < 0.05 each). In conclusion, high SFRP4 immunostaining is associated with poor prognosis and genomic instability in ERG negative prostate cancers.

AB - Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immunohistochemistry. SFRP4 expression was higher in cancer than in non-neoplastic acinar cells. SFRP4 staining was seen in 64.9% of tumors and classified as weak in 33.2%, moderate in 23.9% and strong in 7.8% of cancers. SFRP4 overexpression was linked to advanced tumor stage, high classical/quantitative Gleason grade (p < 0.0001 each), lymph node metastasis (p = 0.0002), and a positive surgical margin (p = 0.0017). SFRP4 positivity was markedly more frequent in ERG positive (77.4%) than in ERG negative cancers (57.4% p < 0.0001). Subset analyses in 2725 cancers with and 3592 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. In a multivariate analysis including various postoperative and prognostic clinico-pathological features, SFRP4 protein expression emerged as an independent prognostic parameter in ERG negative cancers. SFRP4 immunostaining was significantly linked with 10 of 11 previously analyzed chromosomal deletions (p < 0.05 each). In conclusion, high SFRP4 immunostaining is associated with poor prognosis and genomic instability in ERG negative prostate cancers.

U2 - 10.1007/s12253-020-00861-9

DO - 10.1007/s12253-020-00861-9

M3 - SCORING: Journal articles

C2 - 32677026

VL - 26

SP - 2709

EP - 2722

JO - PATHOL ONCOL RES

JF - PATHOL ONCOL RES

SN - 1219-4956

IS - 4

ER -